Calcitonin gene-related peptide terminates long-lasting vasopressor responses to endothelin 1 in vivo

Hypertension

Volumn 58, Issue 1, 2011, Pages 99-106

  Meens, Merlijn J P M T ^a   Mattheij, Nadine J A ^a   Nelissen, Jelly ^a   Lemkens, Pieter ^a   Compeer, Matthijs G ^a   Janssen, Ben J A ^a   De Mey, Jo G R ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

CGRP; endothelin 1; ETA; vascular resistance; vasculature

Indexed keywords

CALCITONIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; NITROPRUSSIDE SODIUM; PHENYLEPHRINE;

ANIMAL EXPERIMENT; ARTERY CONSTRICTION; ARTICLE; BASILAR ARTERY; CONTROLLED STUDY; CORONARY ARTERY; CORONARY BLOOD VESSEL; EPIGASTRIC ARTERY; IN VIVO STUDY; MALE; MESENTERIC ARTERY; MOLECULAR INTERACTION; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; RENAL ARTERY; SAPHENOUS VEIN; SPERMATIC VEIN; SPLEEN ARTERY;

ANIMALS; ARTERIES; BLOOD PRESSURE; CALCITONIN GENE-RELATED PEPTIDE; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; HYPERTENSION; MALE; RATS; RATS, INBRED WKY; REGIONAL BLOOD FLOW; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 79959728878     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.169128     Document Type: Article

References (39)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415. (Pubitemid 18090241)
2. Hynynen MM, Khalil RA. The vascular endothelin system in hypertension- recent patents and discoveries. Recent Pat Cardiovasc Drug Discov. 2006;1:95-108.
3. De Mey J, Compeer M, Meens M. Endothelin-1, an endogenous irreversible agonist in search of an allosteric inhibitor. Mol Cell Pharmacol. 2009;1:246-257.
4. Burkhardt M, Barton M, Shaw SG. Receptor- and non-receptor-mediated clearance of big-endothelin and endothelin-1: differential effects of acute and chronic ETA receptor blockade. J Hypertens. 2000;18:273-279. (Pubitemid 30142843)
5. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun. 1994;199:1461-1465.
6. Nakashima M, Vanhoutte PM. Endothelin-1 and -3 cause endotheliumdependent hyperpolarization in the rat mesenteric artery. Am J Physiol. 1993;265:H2137-H2141.
7. Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol. 2007;47:731-759.
8. Bagnato A, Spinella F, Rosano L. The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol. 2008;86:473-484.
9. Hansen-Schwartz J, Ansar S, Edvinsson L. Cerebral vasoconstriction after subarachnoid hemorrhage-role of changes in vascular receptor phenotype. Front Biosci. 2008;13:2160-2164. (Pubitemid 351589242)
10. Khodorova A, Montmayeur JP, Strichartz G. Endothelin receptors and pain. J Pain. 2009;10:4-28.
11. Masaki T. Historical review: endothelin. Trends Pharmacol Sci. 2004; 25:219-224. (Pubitemid 38519913)
12. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, Fukuroda T, Fukami T, Ozaki S, Nagase T, Nishikibe M, Yano M. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA. 1994;91:4892-4896. (Pubitemid 24177756)
13. Clozel M, Breu V, Gray GA, Kalina B, Loffler BM, Burri K, Cassal JM, Hirth G, Muller M, Neidhart W, Ramuz H. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 1994;270:228-235. (Pubitemid 24229632)
14. Ihara M, Ishikawa K, Fukuroda T, Saeki T, Funabashi K, Fukami T, Suda H, Yano M. In vitro biological profile of a highly potent novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor. J Cardiovasc Pharmacol. 1992;12(suppl):S11-S14. (Pubitemid 23014096)
15. Ohlstein EH, Nambi P, Hay DW, Gellai M, Brooks DP, Luengo J, Xiang JN, Elliott JD. Nonpeptide endothelin receptor antagonists: XI-pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist. J Pharmacol Exp Ther. 1998;286: 650-656. (Pubitemid 29003451)
16. Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol. 2008;153:1105-1119. (Pubitemid 351415492)
17. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA. 2007; 298:2009-2019. (Pubitemid 350074798)
18. Meens MJ, Compeer MG, Hackeng TM, van Zandvoort MA, Janssen BJ, De Mey JG. Stimuli of sensory-motor nerves terminate arterial contractile effects of endothelin-1 by CGRP and dissociation of ET-1/ET(A)- receptor complexes. PLoS One. 2010;5:e10917.
19. Kiely DG, Cargill RI, Struthers AD, Lipworth BJ. Cardiopulmonary effects of endothelin-1 in man. Cardiovasc Res. 1997;33:378-386. (Pubitemid 27072643)
20. Luscher TF, Yang Z, Tschudi M, von Segesser L, Stulz P, Boulanger C, Siebenmann R, Turina M, Buhler FR. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res. 1990;66:1088-1094. (Pubitemid 20126439)
21. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J Clin Invest. 1990;85: 587-590. (Pubitemid 20070070)
22. Wang Y, Wang DH. Prevention of endothelin-1-induced increases in blood pressure: role of endogenous CGRP. Am J Physiol Heart Circ Physiol. 2004;287:H1868-H1874. (Pubitemid 39313297)
23. Hilal-Dandan R, Villegas S, Gonzalez A, Brunton LL. The quasiirreversible nature of endothelin binding and G protein-linked signaling in cardiac myocytes. J Pharmacol Exp Ther. 1997;281:267-273. (Pubitemid 27203077)
24. Talbodec A, Berkane N, Blandin V, Breittmayer JP, Ferrari E, Frelin C, Vigne P. Aspirin and sodium salicylate inhibit endothelin ETA receptors by an allosteric type of mechanism. Mol Pharmacol. 2000;57:797-804. (Pubitemid 30183722)
25. Meens MJ, Fazzi GE, van Zandvoort MA, De Mey JG. Calcitonin gene-related peptide selectively relaxes contractile responses to endothelin-1 in rat mesenteric resistance arteries. J Pharmacol Exp Ther. 2009;331:87-95.
26. Mulvany M, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res. 1977;41:19.
27. De Mey J, Megens R, Fazzi G. Functional antagonism between endogenous neuropeptide Y and calcitonin gene-related peptide in mesenteric resistance arteries. J Pharmacol Exp Ther. 2008;324:930.
28. van Eijndhoven HW, van der Heijden OW, Fazzi GE, Aardenburg R, Spaanderman ME, Peeters LL, De Mey JG. Vasodilator reactivity to calcitonin gene-related peptide is increased in mesenteric arteries of rats during early pregnancy. J Vasc Res. 2003;40:344-350. (Pubitemid 37188103)
29. Burnstock G. Autonomic neurotransmission: 60 years since sir Henry Dale. Annu Rev Pharmacol Toxicol. 2009;49:1-30.
30. Uddman R, Edvinsson L, Ekblad E, Hakanson R, Sundler F. Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects. Regul Pept. 1986;15:1-23. (Pubitemid 16045678)
31. Whalen EJ, Foster MW, Matsumoto A, Ozawa K, Violin JD, Que LG, Nelson CD, Benhar M, Keys JR, Rockman HA, Koch WJ, Daaka Y, Lefkowitz RJ, Stamler JS. Regulation of -adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell. 2007; 129:511-522. (Pubitemid 46660966)
32. Sirvio ML, Metsarinne K, Saijonmaa O, Fyhrquist F. Tissue distribution and half-life of 125I-endothelin in the rat: importance of pulmonary clearance. Biochem Biophys Res Commun. 1990;167:1191-1195. (Pubitemid 20113307)
33. Sabaa N, de Franceschi L, Bonnin P, Castier Y, Malpeli G, Debbabi H, Galaup A, Maier-Redelsperger M, Vandermeersch S, Scarpa A, Janin A, Levy B, Girot R, Beuzard Y, Leboeuf C, Henri A, Germain S, Dussaule JC, Tharaux PL. Endothelin receptor antagonism prevents hypoxiainduced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest. 2008;118:1924-1933. (Pubitemid 351632394)
34. Sexton PM, Morfis M, Tilakaratne N, Hay DL, Udawela M, Christopoulos G, Christopoulos A. Complexing receptor pharmacology: modulation of family B G protein-coupled receptor function by RAMPs. Ann N Y Acad Sci. 2006;1070:90-104. (Pubitemid 44126627)
35. Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev. 2004;84:903-934. (Pubitemid 38823770)
36. Filep JG, Clozel M, Fournier A, Foldes-Filep E. Characterization of receptors mediating vascular responses to endothelin-1 in the conscious rat. Br J Pharmacol. 1994;113:845-852. (Pubitemid 24326824)
37. Kraenzlin ME, Ch'ng JL, Mulderry PK, Ghatei MA, Bloom SR. Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones. Regul Pept. 1985;10:189-197. (Pubitemid 15115429)
38. Kreye VA, Reske SN. Possible site of the in vivo disposition of sodium nitroprusside in the rat. Naunyn Schmiedebergs Arch Pharmacol. 1982; 320:260-265. (Pubitemid 13249548)
39. Kimura S, Kasuya Y, Sawamura T, Shinimi O, Sugita Y, Yanagisawa M, Goto K, Masaki T. Conversion of big endothelin-1 to 21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: structure-activity relationships of big endothelin-1. J Cardiovasc Pharmacol. 1989:13(suppl 5):S5-S7; discussion S18. (Pubitemid 19119202)